Complex Interventional Cardiovascular Therapy - 2017

San Francisco, CA
JULY 21-22, 2017


Target Audience

This educational program is designed for Interventional Cardiologists and Cardiology Fellows,
as well as Physician Assistants and Nurse Practitioners who care for patients undergoing catheter-based cardiovascular interventions.

Educational Goal

The purpose of CICT 2017 symposium will be to promote high quality, efficient, patient-centered decision-making in the field of Interventional Cardiovascular Medicine.

Learning Objectives

  • Evaluate how evidence-based medicine should be incorporated into decision making at the individual patient level
  • Recognize the importance of appropriate triage of patients with complex coronary, structural and peripheral arterial disease to surgical vs. endovascular intervention
  • Explain “tips and tricks” to maximize success and reduce complications in complex cardiovascular interventions
  • Assess best practices to prevent and manage complications in coronary, structural and peripheral interventions

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and Gaffney Events, LLC. The CMEsolutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The CMEsolutions designates this live activity for a maximum of 16.50 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Requirements

  1. Complete sign in sheet
  2. Attend accredited sessions
  3. For credit log on to URL: https://www.online-med-edu.com/cict/portal/2017/ (you are here)
  4. Complete evaluation, credit request form, and download or print credit statement

Faculty and Disclosures

CMEsolutions requires everyone in a position to control the content of this activity to disclose any relevant financial conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CMEsolutions for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Directors

Issam D. Moussa, MD, FACC, FSCAI
Professor of Medicine & Clinical Chief of Cardiology, Rutgers Robert Wood Johnson Medical School; Chief of Cardiology, Robert Wood Johnson University Hospital
New Brunswick, New Jersey
Issam D. Moussa has no relevant financial relationships to disclose.

Joseph De Gregorio, MD, FACC, FSCAI, FACP, FCCP 
Chief of Invasive Cardiology, Englewood Hospital & Medical Center
Englewood, New Jersey
Joseph De Gregorio has disclosed the following relevant financial relationships: Edwards LifeSciences, Spectranetics-Stockholder

Co-Directors

Antonio Colombo, MD, FACC, MSCAI
Director, Cardiac Catheterization Laboratory EMO GVM Centro Cuore Columbus and San Raffaele Hospital
Milan, Italy
Antonio Colombo has no relevant financial relationships to disclose.

Jonathan M. Tobis, MD, FACC, FSCAI
Professor of Medicine Director, Interventional Cardiology Research David Geffen School of Medicine, UCLA
Los Angeles, California
Jonathan M. Tobis has no relevant financial relationships to disclose.

Faculty

Anita Asgar, MD, FRCPC, FACC
Interventional Cardiologist, Montreal Heart Institute Structural Heart Disease Interventional Institute de Cardiologie de Montreal
Montreal, Quebec, Canada
Anita Asgar has disclosed the following relevant financial relationships: Abbott Vascular – Research Support; Edwards LifeSciences, Medtronic – Consultant; Medtronic-Advisory Board

George P. Batsides, MD
Assistant Professor of Surgery chief, Section of Cardiac Surgery Surgical Director Mechanical Circulatory Support, Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ
George P. Batsides has disclosed the following relevant financial relationships: Abiomed-Speaker’s Bureau, Advisory Board;

Malcolm R. Bell, MBBS, FRACP, FACC
Director, Ischemic Heart Disease Program; Professor of Medicine, Mayo Clinic College of Medicine; Consultant, Cardiovascular Diseases, Mayo Clinic
Rochester, MN
Malcolm R. Bell has no relevant financial relationships to disclose.

Robert M. Bersin, MD, MPH, FACC, FSCAI
Medical Director, Endovascular Services, Swedish Heart & Vascular
Seattle, WA
Robert M. Bersin has disclosed the following relevant financial relationships: Advisory Board- Boston Scientific, Cardinal Health, Med Alliance, Transverse Medical; Consulting Relationship-Abbott Vascular, Boston Scientific, Cardinal Health, Cook Medical, Inc., Endologix Corp., Medtronic Vascular, Spectranetics Corp., W.L. Gore; Equity Interest- Ablative Solutions, Boston Scientific, Med Alliance, Vatrix Medical; Grant Support, Omeros Corp., QT Vascular, Transverse Medical; Proctor or Training Course Sponsorships-Abbott Vascular, Cook Medical, Inc., Endologix Corp., Medtronic Vascular, W.L. Gore; Speakers Bureau-Abbott Vascular, Spectranetics Corp.; Spouse Employee- Med Alliance; Stock Options or Positions- Transverse Medical

Emmanouil Brilakis, MD, PhD, FACC, FSCAI
Adjunct Professor of Medicine, UT Southwestern Medical School; Interventional Cardiologist,
Minneapolis Heart Institute
Minneapolis, MN
Emmanouil Brilakis has disclosed the following relevant financial relationships: Abbott Vascular-Consultant, Speaker; Asahi-Speaker; GE Healthcare, Medicure-Consultant, Speaker; Elsevier-Book Sales; Spouse-Employee Medtronic; Boston Scientific-Research Grant

Maurice Buchbinder, MD, FACC, FSCAI
Medical Director, Structural Heart Services; Medical Director, Endovascular Services, San Diego Cardiovascular Associates Foundation for Cardiovascular Medicine
San Diego, CA
Maurice Buchbinder has disclosed the following relevant financial relationships: Boston Scientific-Speaking, Teaching; MValve-Intellectual property rights ownership interest

Gary Gershony, MD
Director of CV Research, Education & Technology, John Muir Health and Cardiovascular Institute
Walnut Creek, CA
Gary Gershony has no relevant financial relationships to disclose.

Steven L. Goldberg, MD, FACC, FSCAI
Medical Director for Structural Heart Disease, Tyler Heart Institute at the Community
Hospital of the Monterey Peninsula (CHOMP)
Monterey, CA
Steven L. Goldberg has disclosed the following relevant financial relationships:  Cardiac Dimensions-Consultant, Chief Medical Officer; Abbott (St. Jude)-Proctor

Adam B. Greenbaum, MD, FACC, FSCAI
Co-Director, Center for Structural Heart Disease, Henry Ford Hospital
Detroit, MI
Adam B. Greenbaum has disclosed the following relevant financial disclosures: Edwards LifeSciences-Proctor; St. Jude Medical-Consultant,  Proctor, Transcaval IDE Registry Support; NIH and Henry Ford Hospital-Intellectual Property Rights

Christopher E. Gribbin, MD
Clinical Associate Professor of Medicine, Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ
Christopher E. Gribbin has no relevant financial relationships to disclose.

Cindy L. Grines, MD, FACC, FSCAI
Medical School Chair & Academic Chief, Cardiology, Hofstra Northwell School of Medicine,
North Shore University Hospital
Manhasset, NY
Cindy L. Grines has no relevant financial relationships to disclose.

Hasan Jilaihawi, MD
Associate Professor, Department of Medicine, Associate Professor, Department of Cardiothoracic Surgery, NYU Langone
New York, NY
Hasan Jilaihawi has disclosed the following relevant financial relationships: Edwards LifeSciences-Consultant; St. Jude Medical-Consultant

R. Stefan Kiesz, MD
Director of Interventional Cardiology
San Antonio Endovascular & Heart Institute
San Antonio, TX
R. Stefan Kiesz has no relevant financial relationships to disclose.

Michael C. Kim, MD, FACC, FSCAI
Director, Cardiac Cath Labs, Director, Interventional Cardiology Fellowship, Associate Professor of Cardiology, Hofstra North Shore-LIJ School of Medicine, Lenox Hill Heart and Vascular Institute
New York, NY
Michael C. Kim has no relevant financial relationships to disclose.

John M. Lasala, MD, PhD, FACC, FSCAI
Professor of Medicine, Washington University School of Medicine, Director, Structural Heart Program, Barnes-Jewish Hospital
St. Louis, MO
John M. Lasala has disclosed the following relevant financial relationships: Abiomed-Consultant, Speaker’s Bureau, Advisory Board; St. Jude Medical/Abbott-Speaker’s Bureau; Boston Scientific-Speaker’s Bureau, Advisory Board; Astra Zeneca-Speaker’s Bureau; E. Lilly/Daiichi Sankyo-Speaker’s Bureau; Edwards LifeSciences-Speaker’s Bureau

Reginald Low, MD, FACC, FSCAI
Chief, Division of Cardiovascular Medicine, University of California, Davis
Sacramento, CA
Reginald Low has disclosed the following relevant financial relationships: Edwards LifeSciences-Proctor;  St. Jude Medical – Proctor, Transcaval IDE Registry Support; Transdermal Systems-Consultant; NIH and Henry Ford Hospital-Equipment for Transcaval Access and Closure

Raj Makkar, MD, FACC
Director, Interventional Cardiology and Cardiac Cath Lab, Cedars-Sinai Medical Center
Los Angeles, CA
Raj Makkar has disclosed the following relevant financial relationships: Cedars-Sinai Medical Center-Employment; Abbott Vascular-Consultant; Cordis-Consultant; Medtronic-Consultant; Edwards LifeSciences-Principal Investigator; St. Jude Medical-Principal Investigator

Verghese Mathew, MD, FACC, FSCAI
Director of Clinical Cardiology, Loyola University Medical Center, Professor of Medicine, Loyola University Stritch School of Medicine, Loyola University Medical Center
Maywood, IL
Verghese Mathew has disclosed the following relevant financial relationship: HLT-Member of DSMB/CEC

Ramon Quesada, MD, FACC, FSCAI, FACP
Medical Director, Interventional Cardiology, Research & Structural Heart Program
Miami Cardiac & Vascular Institute
Miami, FL
Ramon Quesada has no relevant financial relationships to disclose.

Richard Rapoza, PhD
Divisional VP of R&D, Abbott Vascular
Santa Clara, CA
Richard Rapoza has disclosed the following relevant financial relationships: Abbott Vascular, VP of R&D

Campbell Rogers, MD, FACC
Executive Vice President and Chief Medical Officer, Heart Flow, Inc.
Redwood City, CA
Campbell Rogers has disclosed the following relevant financial relationships: HeartFlow, Inc.-Management

John M. Rumsfeld, MD, FACC
National Director of Cardiology, Veterans Health Administration
Denver, CO
John M. Rumsfeld has no relevant financial relationships to disclose.

Mark J. Russo, MD, MS
Director of the Center for Aortic Diseases, Director of Cardiothoracic Surgery Research and
Director of Structural Heart Disease, Assistant Professor of Surgery at Rutgers-New Jersey Medical School, Barnabas Heart Hospital at Newark Beth Israel Hospital
Newark, NJ
Mark J. Russo has no relevant financial relationships to disclose.

Habib Samady, MD
Director, Interventional Cardiology, Professor of Medicine, Director, Cardiac Catheterization Laboratory, Emory Heart & Vascular Center at Clifton, Emory Healthcare Network
Atlanta, GA
Habib Samady has no relevant financial relationships to disclose.

Jorge F. Saucedo, MD, MBA, FACC, FSCAI
Division Head, Cardiology, NorthShore University HealthSystem
Evanston, IL
Jorge F. Saucedo has no relevant financial relationships to disclose.

Richard A. Shlofmitz, MD, FACC, FSCAI
Chairman, Department of Cardiology, St. Francis Hospital, The Heart Center
Roslyn, NY
Richard A. Shlofmitz has disclosed the following relevant financial relationships: Csi-Speaker

Varinder P. Singh, MD, FACC, FSCAI
Chairman, Cardiovascular Medicine, Northwell Health Lenox Hill Heart and Vascular Institute
New York, NY
Varinder P. Singh has no relevant financial relationships to disclose.

Jennifer A. Tremmel, MD, MS, FACC, FSCAI
Assistant Professor of Medicine, Cardiovascular, Clinical Director of Women’s Heart Health
Standard University Medical Center
Stanford, CA
Jennifer A. Tremmel has disclosed the following relevant financial relationships: Terumo, Medtronic, Boston Scientific, St. Jude/Abbott-Consulting, Speaking, Teaching; Recor-Stock Options

Ron Waksman, MD, FACC, FSCAI
Director, Cardiovascular Research and Advanced Education, Professor of Cardiology,  Georgetown University, Associate Director, Division of Cardiology, Medstar Heart Institute
Washington, DC
Ron Waksman has disclosed the following relevant financial relationships: Amgen, Medtronic, Philips Volcano, Abbott Vascular-Advisory Board, Consultant; Biosensors, Biotronik, Boston Scientific-Consultant

Giora Weisz, MD
Associate Professor of Clinical Medicine, Columbia University, Director of Clinical Cardiovascular, Research, New York-Presbyterian Hospital, Columbia University Medical Center
New York, NY
Giora Weisz has Corindus-Consultant; Filterlex-Co-founder; TriSol, Medical Incentives, Vectorious-Consulting

Michael Wilderman, MD
Chief of Endovascular Surgery, Heart & Vascular Hospital, Hackensack University Medical Center
Hackensack, NJ
Michael Wilderman has no relevant financial relationships to disclose.

Steven J. Yakubov, MD, FACC, FSCAI
System Chief, Structural Heart Disease, John H McConnell Chair of Advanced
Structural Heart Disease, Medical Director, OhioHealth Research Institute, Riverside Methodist Hospital
Columbus, OH
Steven J. Yakubov has disclosed the following relevant financial relationships: Medtronic, Boston Scientific, BioStar, Abbott Vascular-Consultant

Ramzan M. Zakir, MD FACC, FSCAI
Clinical Assistant Professor of Medicine, Rutgers Medical School, Robert Wood Johnson University Hospital, Director, Transradial Catherization, Director, Peripheral Vascular Institute, Saint, Peter’s University Hospital
New Brunswick, NJ
Ramzan M. Zakir has disclosed the following relevant financial relationships: Abbott, Astra Zeneca, Cardiovascular Systems In., Medtronic – Speaking/Teaching; Spectranetics, Bard, Terumo-Consultant

Planner Disclosure

No member of CMEsolutions or Gaffney Events, LLC.  has any relevant financial relationships to disclose.

Fees

The registration fee for this CME activity is $475.00 for physicians and $375.00 for Residents, Nurses and Technicians. Registration Fees are waived for Fellows in Training. The registration fee for Industry Personnel is $450.00.

Off-label Use

CICT 2017 may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA.  Please consult the prescribing information for each product.

Commercial Support

Commercial support for this activity is provided by the following:
Abbott Laboratories
Abiomed, Inc.
Boston Scientific Corporation
Chiesi
Cook Medical, LLC
EKOS Corporation
Medtronic Cardiac and Vascular Group
St. Jude Medical

Privacy Policy

CMEsolutions Privacy and Confidentiality Policy: www.online-med-edu.com/privacypolicy.pdf
CMEsolutions can be contacted at info@cmesolutions.org.


 complete evaluation/credit request